SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 5.74 |
| Enterprise Value ($M) | 38.95 |
| Book Value ($M) | 3.87 |
| Book Value / Share | 2.18 |
| Price / Book | 1.48 |
| NCAV ($M) | -12.74 |
| NCAV / Share | -7.18 |
| Price / NCAV | -0.45 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.26 |
| Return on Assets (ROA) | -0.65 |
| Return on Equity (ROE) | -1.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.06 |
| Current Ratio | 1.23 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.12 |
| Assets | 24.74 |
| Liabilities | 20.86 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Novalis LifeSciences Investments II, L.P. | 19.99 | -94.33 | |
| 13D/A | Northpond Ventures, LP | 47.60 | -94.36 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| SWGHF – Sawai Group Holdings Co., Ltd. | SYBE – Sybleu Inc. |
| TBEV – High Performance Beverages Company | TCNNF – Trulieve Cannabis Corp. |
| TEVJF – Teva Pharmaceutical Industries Limited |
Financial data and stock pages provided by
Fintel.io